What is the status of AMERISAFE's buyback authorization?

The Company has $7.3 million of remaining authorization under its share repurchase program as of June 30, 2026. The program has been active since 2010 and does not obligate the Company to repurchase shares; it may be modified, suspended, or terminated at the Board's discretion.

How have total cumulative repurchases compared to the execution price?

Since 2010, AMERISAFE has repurchased 2,278,192 shares at an average cost of $28.01 per share for a total of $63.8 million. The Q2 2026 execution at $30.58 per share is above the program's historical average, reflecting market conditions at the time of repurchase.

How did share repurchases affect AMERISAFE's financial results?

The Company disclosed that capital returned to shareholders through both dividends and share repurchases reduced average investable assets during the quarter, which contributed to a 2.4% decline in net investment income compared to the prior-year period, partially offset by higher book yield.

What mechanism is used for executing these buybacks?

AMERISAFE states that repurchases may be effected from time to time pursuant to Rule 10b5-1 trading plans, which allow companies to establish predetermined repurchase schedules to avoid concerns about insider trading.

How does the Q2 buyback relate to AMERISAFE's capital management strategy?

The repurchase is part of AMERISAFE's disciplined capital management approach, alongside a 5.1% increase in its quarterly dividend to $0.41 per share. The Company emphasizes balance between returning capital to shareholders and maintaining strong underwriting discipline and balance-sheet strength.

AMSF 8-K Filed 2026-07-21 Execution disclosure

AMERISAFE repurchased 184,093 shares at $30.58 average in Q2 2026

Workers' compensation insurer executed Q2 buyback under existing authorization; $7.3M remaining capacity

Shares repurchased184K

Avg price paid$30.58

Remaining$7M

MechanismRule 10b5-1 plan (as noted: ma

What the filing says

AMERISAFE, Inc. (Nasdaq: AMSF), a specialty workers' compensation insurer, announced in its second-quarter 2026 earnings release that it repurchased 184,093 shares of common stock during the quarter at an average cost of $30.58 per share, including commissions and excise tax, for a total of $5.6 million. The repurchases were executed under the Company's share repurchase program, which has been active since 2010.

Since inception of the program in 2010, AMERISAFE has repurchased a cumulative 2,278,192 shares at an average cost of $28.01 per share for a total outlay of $63.8 million. As of June 30, 2026, the Company had $7.3 million of remaining authorization under the program. The filing notes that repurchases may be effected from time to time pursuant to Rule 10b5-1 trading plans, and the repurchase program does not obligate the Company to repurchase shares and may be modified, suspended, or terminated at the Board's discretion.

The Company also highlighted that capital returned to shareholders through dividends and share repurchases reduced average investable assets and contributed to a 2.4% decline in net investment income for the quarter compared to the prior-year period.

Also during the quarter, the Company repurchased 184,093 shares of its common stock under the Company's share repurchase program at an average cost of $30.58 per share, including commissions and excise tax, for a total of $5.6 million. — AMERISAFE INC 8-K filing · View on SEC EDGAR →

What this means

AMERISAFE's Q2 2026 repurchase of 184,093 shares represents continued execution of its long-standing (since 2010) share buyback program, which has returned $63.8 million to shareholders over 16 years. The $5.6 million quarterly outlay is modest relative to the Company's quarterly net income of $14.6 million, reflecting measured capital deployment. The $7.3 million remaining authorization provides limited capacity for future buybacks without Board action. The Company disclosed that these repurchases, combined with dividend payments, reduced average investable assets and contributed to lower net investment income in the quarter—a mechanical reminder that share returns compete with balance-sheet growth and investment yield.

Frequently asked questions

How much did AMERISAFE spend on share repurchases in Q2 2026?: AMERISAFE repurchased 184,093 shares at an average cost of $30.58 per share (including commissions and excise tax) for a total of $5.6 million during the second quarter of 2026.
What is the status of AMERISAFE's buyback authorization?: The Company has $7.3 million of remaining authorization under its share repurchase program as of June 30, 2026. The program has been active since 2010 and does not obligate the Company to repurchase shares; it may be modified, suspended, or terminated at the Board's discretion.
How have total cumulative repurchases compared to the execution price?: Since 2010, AMERISAFE has repurchased 2,278,192 shares at an average cost of $28.01 per share for a total of $63.8 million. The Q2 2026 execution at $30.58 per share is above the program's historical average, reflecting market conditions at the time of repurchase.
How did share repurchases affect AMERISAFE's financial results?: The Company disclosed that capital returned to shareholders through both dividends and share repurchases reduced average investable assets during the quarter, which contributed to a 2.4% decline in net investment income compared to the prior-year period, partially offset by higher book yield.
What mechanism is used for executing these buybacks?: AMERISAFE states that repurchases may be effected from time to time pursuant to Rule 10b5-1 trading plans, which allow companies to establish predetermined repurchase schedules to avoid concerns about insider trading.
How does the Q2 buyback relate to AMERISAFE's capital management strategy?: The repurchase is part of AMERISAFE's disciplined capital management approach, alongside a 5.1% increase in its quarterly dividend to $0.41 per share. The Company emphasizes balance between returning capital to shareholders and maintaining strong underwriting discipline and balance-sheet strength.

execution rule-10b5-1 specialty-insurance mid-cap Q2-2026 ongoing-program

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.